A competition aimed at tackling unequal access to healthcare in the NHS has been won by C2-Ai, a company that has developed an artificial intelligence-based risk assessmen
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh